Giancarlo Agnelli - Concepedia

Author

Giancarlo Agnelli

Also Known As

Agnelli G, Alexander S. Gallus, Cecilia Becattini, G Agnelli, G. AGNELLI, G. Agnelli, GIANCARLO AGNELLI, Giancarlo Agnelli, Harry R. Buller, Jack Ansell

268

Publications

20.1K

Citations

H-Index

Concepts

All Affiliations

University of Perugia McMaster University Thrombosis Research Institute Amsterdam UMC Location University of Amsterdam University of Oklahoma Health Sciences Center

About

Giancarlo Agnelli is an author at University of Perugia specializing in medicine, thrombosis, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	50	5.5K
2	Health Sciences	12	12	974
3	Public Health	8	8	554
4	Engineering	1	1	11
5	Biomolecular Engineering	1	1	11

Giancarlo Agnelli

Publications

13.3K

Citations

H-Index

Page 1

	Year	Citations
Oral Apixaban for the Treatment of Acute Venous Thromboembolism Giancarlo Agnelli, Harry R. Büller, Alexander T. Cohen, New England Journal of Medicine	2013	2.2K
Antithrombotic Therapy for Venous Thromboembolic Disease Clive Kearon, Susan R. Kahn, Giancarlo Agnelli, CHEST Journal ThrombosisVenous DiseaseVenous ThrombosisAntithrombotic TherapyHematology	2008	2K
Apixaban for Extended Treatment of Venous Thromboembolism Giancarlo Agnelli, Harry R. Büller, Alexander T. Cohen, New England Journal of Medicine	2012	1.3K
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer David Bergqvist, Giancarlo Agnelli, Alexander T. Cohen, New England Journal of Medicine	2002	1K
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Giancarlo Agnelli, Gualberto Gussoni, C. Bianchini, The Lancet Oncology ThrombosisMedicinePharmacologyDouble-blind StudyAmbulatory Patients	2009	591
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials Florent Boutitie, L. Pinède, Sam Schulman, BMJ	2011	366
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study Harry R. Büller, Anthonie W.A. Lensing, Martin H. Prins, Blood	2008	345
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939) Giancarlo Agnelli, Alexander Gallus, Samuel Z. Goldhaber, Circulation	2007	340
Randomized clinical trial of postoperative fondaparinux <i>versus</i> perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery Giancarlo Agnelli, David Bergqvist, Alexander T. Cohen, British journal of surgery	2005	338
PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma James Perry, J.A. Julian, Normand Laperrière, Journal of Thrombosis and Haemostasis Neuro-oncologyThrombosisGliomaMedicineHematology	2010	245

Page 1